The Future of Ophthalmology Therapeutics, Analysis and Market Forecasts to 2016

GBI Research's report, "The Future of4.3.5 Annual Cost of Therapy 58
Ophthalmology Therapeutics, Analysis and Market4.3.6 Treatment Usage Patterns 59
Forecasts to 2016 – Strategies to Counter4.3.7 Geographical Segmentation 65
Generic Erosion in Key Markets", provides in-depth4.3.8 Drivers of Macular Degeneration Market 67
analysis of the unmet needs, drivers and barriers4.3.9 Restraints for Macular Degeneration Market
that impact the global ophthalmology therapeutics67
market. The report analyzes the ophthalmology4.4 Allergic Conjunctivitis Market 68
markets in the US, the top five countries in4.4.1 Introduction 68
Europe (the UK, Germany, France, Italy and4.4.2 Unmet Needs 68
Spain) and Japan. Treatment usage patterns,4.4.3 Sales Value 69
sales, prices and volume are forecast until 20164.4.4 Sales Volume 70
for the key geographies as well as the leading4.4.5 Annual Cost of Therapy 71
therapeutic segments. Further, the report4.4.6 Treatment Usage Patterns 72
provides competitive benchmarking for the leading4.4.7 Geographical Segmentation 78
companies and analyzes the mergers, acquisitions4.4.8 Drivers of Allergic Conjunctivitis Market 80
and licensing agreements that shape the global4.4.9 Restraints for Allergic Conjunctivitis Market
markets.80
This report is built using data and information5 Global Ophthalmology Therapeutics Market:
sourced from proprietary databases, primary andGeographical Landscape 81
secondary research and in-house analysis by GBI5.1 Geographical Break-up 81
Research's team of industry experts.5.2 The US 82
Scope5.2.1 Sales Value 82
The scope of this report includes:5.2.2 Annual Cost of Therapy 83
- Annualized market data for the ophthalmology5.2.3 Treatment Usage Patterns 84
market from 2001 to 2009, forecast forward to5.3 Top Five Countries in Europe 90
2016.5.3.1 Sales Value 90
- Analysis of the leading therapeutic segments,5.3.2 Annual Cost of Therapy 91
including glaucoma, macular degeneration, macular5.3.3 Treatment Usage Patterns 92
edema and allergic conjunctivitis.5.4 Japan 96
- Analysis of the ophthalmology market in the5.4.1 Sales Value 96
leading geographies of the world, which include the5.4.2 Annual Cost of Therapy 97
US (United States), the UK (United Kingdom),5.4.3 Treatment Usage Patterns 98
Germany, France, Italy, Spain and Japan.6 Global Ophthalmology Therapeutics Market:
- Market characterization of the ophthalmologyPipeline Analysis 104
market including market size, the annual cost of6.1 Introduction 104
therapy, sales volume and treatment usage6.2 Research and Development Pipeline by Phase
patterns.104
- Key drivers and barriers that have a significant6.2.1 Research and Development Pipeline –
impact on the market.Macular Degeneration 105
- Coverage of pipeline molecules in the various6.2.2 Research and Development Pipeline –
phases of drug development.Glaucoma 106
- Competitive benchmarking of leading companies6.2.3 Research and Development Pipeline –
such as Pfizer, Allergan, Inc., Alcon, Inc., NovartisMacular Edema 106
AG, Merck & Co Inc and Roche.6.2.4 Research and Development Pipeline –
- Key M&A activities that have taken place inAllergic Conjunctivitis 107
2009 and the licensing agreements in the6.3 R&D Trends 107
2008-2009 global ophthalmology market.6.3.1 New Promising Treatments for Diabetic
Reasons to buyRetinopathy 107
The report will enhance your decision making6.3.2 Combination Drugs Will be a Key Component
capability. It will allow you to:of Ophthalmology Research and Development 107
- Align your product portfolio to the markets with6.4 Profiles of Key Drugs in the Glaucoma Pipeline
high growth potential.108
- Develop market-entry and market expansion6.4.1 Saflutan (tafluprost) 108
strategies by identifying the leading therapeutic6.4.2 NCX-116 (Formerly PF-03187207) 108
segments and geographic markets poised for6.4.3 Catioprost 109
strong growth.6.5 Profiles of Key Drugs in Macular Edema and
- Reinforce R&D pipelines by identifying newDiabetic Retinopathy Pipeline 110
target mechanisms which can produce6.5.1 Iluvien 110
first-in-class molecules with more efficiency and6.5.2 iCo-007 111
better safety.6.6 Profiles of Key Drugs in Macular Degeneration
- Develop key strategic initiatives byPipeline 111
understanding the key focus areas of the leading6.6.1 ACU-4429 111
companies.6.6.2 AL-8309 112
- Exploit in-licensing and out-licensing opportunities6.7 Profiles of Key Drugs in Allergic Conjunctivitis
by identifying products that could fill portfolio gaps.Pipeline 112
Table of Content6.7.1 FOV1101 (Prednisporin) 112
1 Table of Contents 37 Global Ophthalmology Therapeutics Market:
1.1 List of Tables 6Competitive Landscape 113
1.2 List of Figures 107.1 Market Share Analysis: Ophthalmology 113
2 Global Ophthalmology Therapeutics Market:7.2 Competitive Profiling 115
Introduction 137.2.1 Pfizer 115
2.1 GBI Research Report Guidance 137.2.2 Allergan, Inc. 116
3 Global Ophthalmology Therapeutics Market:7.2.3 Alcon, Inc. 118
Market Overview 147.2.4 Novartis AG 120
3.1 Introduction 147.2.5 Merck & Co Inc 122
3.2 Revenue Forecasts for the Global7.2.6 Roche 123
Ophthalmology Therapeutics Market 148 Global Ophthalmology Therapeutics Market:
3.2.1 Sales Value 14Strategic Consolidations 125
3.2.2 Annual Cost of Therapy 158.1 Overview 125
3.2.3 Treatment Usage Patterns 178.1.1 Valeant Pharmaceuticals International Agrees
3.2.4 Generics' Share in the Global Ophthalmologyto Acquire Aton Pharma Inc 126
Therapeutics Market 238.1.2 Healthcare of Today, Inc. has Acquired
3.2.5 Sales of Leading Drugs 25MacuCLEAR, Inc. 126
4 Global Ophthalmology Therapeutics Market:8.1.3 Opko Health, Inc. has Acquired Pharmacos
Therapeutic Landscape 26Exakta 126
4.1 Glaucoma Market 268.1.4 Sanofi-aventis Acquired Fovea
4.1.1 Introduction 26Pharmaceuticals 126
4.1.2 Unmet Needs 278.1.5 Alcon, Inc Acquired ESBATech AG 126
4.1.3 Sales Value 288.1.6 Aton Pharma, Inc. Acquired Marketing Rights
4.1.4 Sales Volume 29to Ophthalmology Drug 126
4.1.5 Annual Cost of Therapy 308.2 R&D Licensing Agreements 127
4.1.6 Treatment Usage Patterns 328.2.1 General 127
4.1.7 Geographical Segmentation 398.2.2 Preclinical and Discovery 127
4.1.8 Drivers of the Glaucoma Market 418.2.3 Phase I 128
4.1.9 Restraints for Glaucoma Market 418.2.4 Phase II 130
4.2 Macular Edema 428.2.5 Phase III 130
4.2.1 Introduction 428.2.6 Approved 131
4.2.2 Unmet Needs 429 Global Ophthalmology Therapeutics Market:
4.2.3 Sales Value 43Appendix 133
4.2.4 Sales Volume 449.1 Market Definitions 133
4.2.5 Annual Cost of Therapy 459.2 Abbreviations 133
4.2.6 Treatment Usage Patterns 469.3 Research Methodology 134
4.2.7 Geographical Segmentation 529.3.1 Coverage 134
4.2.8 Drivers of the Macular Edema Market 549.3.2 Secondary Research 135
4.2.9 Restraints For Macular Edema Market 549.3.3 Primary Research 135
4.3 Macular Degeneration Market 549.3.4 Forecasts 135
4.3.1 Introduction 549.3.5 Expert Panel Validation 137
4.3.2 Unmet Needs 559.4 Contact Us 138
4.3.3 Sales Value 559.5 Disclaimer 138
4.3.4 Sales Volume 569.